EYPT Q3 2020 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M+525.5% YoY

Gross Profit

$14M88.0% margin

Operating Income

-$2M-12.5% margin

Net Income

-$4M-24.2% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

+280.8%

Cash Flow

Operating Cash Flow

$1M

Free Cash Flow

$1M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$77M

Total Liabilities

$69M

Stockholders' Equity

$8M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$3M	+525.5%
Gross Profit	$14M	$2M	+533.0%
Operating Income	-$2M	-$14M	+86.1%
Net Income	-$4M	-$16M	+75.7%

Revenue Segments

Product

$6M50%

Y U T I Q Product

$3M30%

D E X Y C U Product

$2M20%